Korro Bio starts dosing in KRRO-121 trial, faces Novo Nordisk termination

Korro Bio reported on November 5, 2026 that it dosed the first cohort in ANCHOR, its global Phase 1/2 clinical trial program for KRRO-121 in healthy volunteers and participants with UCD, registered as NCT07773246¹. The company said it started the Part 1 single ascending dose portion in September 2026, enrolling up to 30 healthy volunteers across up to five cohorts, placebo-controlled at each dose level¹. Korro expects to begin dosing UCD patients in the first half of 2027, with an interim clinical readout expected in the second half of 2027¹.

For KRRO-111 in alpha-1 antitrypsin deficiency, Korro reported preclinical data showing it achieved greater than 95% editing of SERPINA1 transcripts in a repeat-dose study in NSG PiZZ mice, with functional M-AAT making up approximately 93% of total circulating AAT and total AAT reaching 172μM, about six-fold above vehicle at Day 57¹. In a separate liver model, a near-complete elimination of approximately 95% of the pathogenic liver Z-AAT was observed¹. The company said it plans a regulatory submission for KRRO-111 in the first half of 2027¹.

Separately, Korro disclosed in the same 8-K that on November 3, 2026, it received written notice from Novo Nordisk A/S of its election to terminate for convenience the research collaboration and license agreement dated September 13, 2024, as amended November 11, 2025¹, with the termination effective February 1, 2027¹. Korro said it received a $10.0 million upfront payment and reimbursement of certain research and development costs, and was eligible for milestone payments and royalties, though no milestone payments were earned¹.

Korro ended the quarter with $124.8 million in cash, cash equivalents and marketable securities as of September 30, 2026, compared to $85.2 million at the end of 2025¹, which the company said is expected to fund operations into the second half of 2028¹.